TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05501561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04945070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGlarLixi
Description: Switching T2DM subjects from MDI to iGlarLixi

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI - Multiple dose insulin injection
Description: Continuing with established MDI regimen
Study: NCT05997329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App for diet record (MyFood)
Description: Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
Study: NCT06255704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib and RCHOP/RDHAP
Description: Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。
Study: NCT05246436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warming saline media
Description: use warm saline as a distention media in office hysteroscopy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: room temperature saline media
Description: use room temperature saline as a distention media in office hysteroscopy
Study: NCT06535243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifespan Integration Therapy (LI)
Description: same as above
Study: NCT05074251

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self test
Description: For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use \& importance of partner testing, to take home to their partner(s).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling and referral for partner testing
Description: Counseling and refer participant's partner for facility based HIV testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and referral for partner testing
Description: Counseling and refer participant's partner for facility based HIV testing
Study: NCT05886790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
Description: Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent COVID-19 mRNA Vaccine
Description: Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
Description: Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
Study: NCT04658901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERA-C70,ERA-C30 and ERA-G5
Description: use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFast™ and ClosureRFG™
Description: use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
Study: NCT06120400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Whole Egg
Description: Whole Large, Grade A Egg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Egg
Description: Whole Large, Grade A Egg
Study: NCT05768451

Intervention type: OTHER
Intervention: Ultrasonic image analysis
Description: Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.

Intervention type: OTHER
Intervention: Ultrasonic image analysis
Description: Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
Study: NCT05068466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Administered Orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study: NCT06360250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation
Description: Each dose (1.0 ml) contained 1.25 mg of human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of human anti-tetanus toxin monoclonal antibody B86.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus human immunoglobulin (HTIG)
Description: Tetanus human immunoglobulin (HTIG)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo
Description: There were no active ingredients, and other ingredients were the same

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed tetanus vaccine (TT)
Description: containing tetanus toxoid titer not less than 40 IU

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adsorbed tetanus vaccine (TT)
Description: containing tetanus toxoid titer not less than 40 IU

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed tetanus vaccine (TT)
Description: containing tetanus toxoid titer not less than 40 IU
Study: NCT05279248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV+MMR（0d），HPV（6m）
Description: Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV（0d），HPV（6m），MMR（7m）
Description: Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR（0d），HPV（1m），HPV（7m）
Description: Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
Study: NCT06474949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine injection
Description: Injection at end of Open Reduction Internal Fixation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection at end of Open Reduction Internal Fixation
Study: NCT06398847

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Reality headset
Description: Self-hypnosis software in a Virtual Reality headset. This is the development of software that provides a self-hypnosis experience that can be inserted into any virtual reality device.
Study: NCT06001658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.
Study: NCT05839275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, d1, q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy).
Study: NCT04860570

Intervention type: DEVICE
Intervention: Double-ring wound-edge protector
Description: Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
Study: NCT04544475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revaree
Description: Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace
Description: Vaginal estrogen cream, estradiol: 100mcg
Study: NCT05125055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab (anti-programmed death-1 inhibitor)
Description: The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
Study: NCT05168800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue-Based Webinar
Description: One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Website
Description: A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Practice
Description: COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
Study: NCT05445375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAD education video
Description: 20-min online multi-media video
Study: NCT05774236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook´s balloon
Description: Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal dinoprostone
Description: Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
Study: NCT05523037

Intervention type: DRUG
Intervention: Sevoflurane
Description: For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration

Intervention type: DRUG
Intervention: Remimazolam
Description: For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
Study: NCT04702802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 3%
Description: During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 3%
Description: During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
Study: NCT04629820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
Study: NCT04697238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight vest
Description: A vest weighing up to a maximum of 15 kg.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Weight vest
Description: A vest weighing up to a maximum of 15 kg.
Study: NCT05984342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
Study: NCT05153083

Intervention type: PROCEDURE
Intervention: Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)
Description: Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
Study: NCT04980482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: subcutaneous injection
Study: NCT05991635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gatekeeper training (e-learning)
Description: The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~* Background information on suicide in Flanders (rates)~* Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~* Debunking existing myths about suicide~* The role of the pharmacist in suicide prevention~* Signal Recognition~* Talking about suicide and suicidal thoughts (start the conversation)~* How and to whom to refer as pharmacist or FTA~* Medication management and medication in the context of suicide~* Rights and obligations of a pharmacist/PTA in the context of suicide prevention~* Self-care
Study: NCT06384209

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friendship Bench intervention
Description: Trained Lay Health Workers (LHWs) deliver six weekly sessions of the Problem Solving Therapy on a bench in a discreet area on the premises of the PHC. Each session consists of four stages, namely opening the mind, uplifting, strengthening and re-strengthening. Opening up the mind includes psychoeducation and normalizing depression as a mental health condition. The aim of uplifting is to identify and formulate the problems that could contribute to depressed mood. Patients categorize and rate each problem in terms of its importance and potential solvability and brainstorm lists of possible solutions. In the next stage, strengthening, clients are encouraged to consider the pros and cons of potential solutions. The LHW helps them recognize potentially dysfunctional problem-solving and develop a realistic plan to resolve the prioritized problem. In the final stage, further strengthening, participants are reassured and encouraged that the goals they set can be achieved.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention
Description: Trained Lay Health Workers (LHWs) deliver six weekly sessions of the Problem Solving Therapy on a bench in a discreet area on the premises of the PHC. Each session consists of four stages, namely opening the mind, uplifting, strengthening and re-strengthening. Opening up the mind includes psychoeducation and normalizing depression as a mental health condition. The aim of uplifting is to identify and formulate the problems that could contribute to depressed mood. Patients categorize and rate each problem in terms of its importance and potential solvability and brainstorm lists of possible solutions. In the next stage, strengthening, clients are encouraged to consider the pros and cons of potential solutions. The LHW helps them recognize potentially dysfunctional problem-solving and develop a realistic plan to resolve the prioritized problem. In the final stage, further strengthening, participants are reassured and encouraged that the goals they set can be achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants -Fluoxetine
Description: If randomised to the intervention arm, participants will be prescribed the first dose of Fluoxetine 20mg or Sertraline 50mg if breastfeeding. They will receive weekly Friendship Bench sessions as in the control arm. The antidepressants will be tapered on the third study visit to Fluoxetine 40mg or Sertraline 100mg.The next tapering will be done on the sixth study visit. The general nurse will be informed on the treatment response and increase Fluoxetine to 60mg and Sertraline to 150mg in patients of the intervention arm without partial response defined as \<30% improvement in PHQ-9 as compared to baseline.